Stock EXAI EXSCIENTIA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Exscientia plc

Equities

EXAI

US30223G1022

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.99 USD -3.39% Intraday chart for Exscientia plc -8.49% -37.75%
Mar. 21 Exscientia Files $300 Million Mixed Shelf MT
Mar. 21 Transcript : Exscientia plc, 2023 Earnings Call, Mar 21, 2024

Business Summary

Exscientia PLC is a United Kingdom-based artificial intelligence (AI)-driven precision medicine company. It is focused on discovering, designing and developing the possible drugs. It has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Precision Target, Precision Design, Precision Experiment, Precision Medicine, Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Its advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.

Number of employees: 483

Sales per Business

USD in Million2022Weight2023Weight Delta
Licensing Fees
99.5 %
33 97.5 % 25 99.5 % -24.08%
Service Fees
0.5 %
1 2.5 % 0 0.5 % -84.34%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
71.6 %
26 77.1 % 18 71.6 % -30.87%
France
25.3 %
-- 6 25.3 % -
Rest of Europe
3.1 %
8 22.9 % 1 3.1 % -89.97%

Managers

Managers TitleAgeSince
David Hallett CEO
 Chief Executive Officer 54 20-01-20
Ben Taylor DFI
 Director of Finance/CFO 46 20-11-17
Eileen Jennings-Brown CTO
 Chief Tech/Sci/R&D Officer - 22-04-30
Michael Krams CTO
 Chief Tech/Sci/R&D Officer 63 22-04-05
Sara Blum Sherman IRC
 Investor Relations Contact - 21-07-31
Dan Ireland LAW
 General Counsel - -
Chris Thomas PRN
 Corporate Officer/Principal - 19-11-30
Richard Henry Cheetham Bickerton PRN
 Corporate Officer/Principal 80 20-12-31
Caroline Rowland HRO
 Human Resources Officer - 22-09-07
John Overington PRN
 Corporate Officer/Principal - 21-06-30

Members of the board

Members of the board TitleAgeSince
Mario Polywka BRD
 Director/Board Member 61 17-09-27
Elizabeth Crain CHM
 Chairman 59 21-02-08
Ben Taylor DFI
 Director of Finance/CFO 46 20-11-17
Robert Ghenchev BRD
 Director/Board Member 41 20-04-30
David Hallett CEO
 Chief Executive Officer 54 20-01-20
Franziska Michor BRD
 Director/Board Member 41 23-05-02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 125,702,396 90,820,021 ( 72.25 %) 0 36.07 %
Stock B 1 126,119,566 0 0

Shareholders

NameEquities%Valuation
SoftBank Capital Partners LLC
4.505 %
5,681,818 4.505 % 32 M $
Laurion Capital Management LP
4.289 %
5,409,533 4.289 % 31 M $
Baillie Gifford & Co.
3.719 %
4,690,480 3.719 % 27 M $
Platinum Investment Management Ltd.
3.242 %
4,088,318 3.242 % 23 M $
Woodline Partners LP
1.303 %
1,642,942 1.303 % 9 M $
Pivotal Bioventure Partners Investment Advisor LLC
1.293 %
1,630,392 1.293 % 9 M $
Bill & Melinda Gates Foundation
1.261 %
1,590,909 1.261 % 9 M $
MIC Capital Management UK LLP
1.223 %
1,542,600 1.223 % 9 M $
Marshall Wace LLP
1.031 %
1,300,068 1.031 % 7 M $
BlackRock Fund Advisors
0.4985 %
628,660 0.4985 % 4 M $
NameEquities%Valuation
Andrew Hopkins
16.17 %
19,124,900 16.17 % 109 M $
EVOTEC SE
11.86 %
14,035,200 11.86 % 80 M $
SB Investment Advisers (UK) Ltd.
11.24 %
13,295,400 11.24 % 76 M $
Elizabeth Crain
0.0596 %
70,498 0.0596 % 403 249 $
Mario Polywka
0.0526 %
62,198 0.0526 % 355 773 $
Ben Taylor
0.0414 %
48,996 0.0414 % 280 257 $
Michael Krams
0.0296 %
35,050 0.0296 % 200 486 $
Franziska Michor
0.005590 %
6,613 0.005590 % 37 826 $
David Hallett
0.001268 %
1,500 0.001268 % 8 580 $

Company contact information

Exscientia Plc

The Schrödinger Building Oxford Science Park

OX4 4GE, Oxford

+

http://www.exscientia.ai
address Exscientia plc(EXAI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Exscientia plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3.193 GBP
Average target price
6.873 GBP
Spread / Average Target
+115.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EXSCIENTIA PLC Stock Exscientia plc
-37.75% 522M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EXAI Stock
  4. Company Exscientia plc